A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries a risk of bleeding and infection. Findings from this research may offer a more accurate and reliable method to diagnose prostate cancer.
“This study is exciting because it has the potential to offer a non-invasive alternative to the traditional PSA test in order to diagnose significant prostate cancers,” said Craig Rogers, M.D., chair of the Vattikuti Urology Institute at Henry Ford Health System. “The discovery of new biomarkers ultimately benefits our patients, as it advances our understanding of this complex disease and how to most effectively treat it.”
When the KLK4 protein coding gene and KLKP1 pseudogene fuse together, the fusion gene KLK4-KLKP1 is formed. Pseudogenes like KLKP1 are the non-functional, or dead, versions of an actual gene that is normally not expressed in a cell but can become active in cancerous cells and disrupt the functions of the actual gene.
“The unique feature of this fusion gene is the conversion of the noncoding pseudogene KLKP1 into a protein coding gene, and its unique expression in about 30 percent of high Gleason grade prostate cancer,” said Dr. Palanisamy. “Like other ETS family gene fusions, KLK4-KLKP1 can also be detected in the urine samples of patients with prostate cancer, enabling non-invasive detection of prostate cancer. Given the unique feature of this fusion, prostate cancer specific expression, oncogenic properties and noninvasive detection, this novel gene fusion has the potential to be used as a biomarker for early detection of prostate cancer and a therapeutic target.”
The researchers conducting this study screened a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients of other races), which revealed that the KLK4-KLKP1 fusion gene is expressed in about 32 percent of prostate cancer patients, representing a distinct subset of prostate cancer cases. Correlative analysis showed that the new fusion gene can be used in combination with other prostate cancer molecular markers for cancer detection. In addition to urine samples, the fusion could also be detected in needle biopsy tissue samples by using a specific antibody.
Prostate cancer is the most common cancer among men in the United States. Advances in diagnosis, treatment, and management have resulted in increased survival rates, yet prostate cancer still remains the second leading cause of cancer-related deaths among American men. One of the major barriers to achieving successful prostate cancer control is the underlying molecular complexity of the disease itself.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometryon October 18, 2019 at 2:07 am
Fresh prostate cancer specimens were obtained with written informed consent through the Australian Prostate Cancer BioResource collection from men undergoing robotic radical prostatectomy at St Andrew ...
- Prostate Cancer: Epidemiology Forecast to 2028on October 17, 2019 at 5:26 pm
New York, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Prostate Cancer: Epidemiology Forecast to 2028" - ...
- Tobacco smoking and death from prostate cancer in US veteranson October 17, 2019 at 6:54 am
Cigarette smoking is a risk factor for mortality in several genitourinary cancers, likely due to accumulation of carcinogens in urine. However, in prostate cancer (PC) the link has been less studied.
- U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Is Projected To Reach $389.1 Million By 2026: Grand View Research, Inc.on October 17, 2019 at 4:35 am
Oct 17, 2019 (AB Digital via COMTEX) -- The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach over USD 389.1 million by 2026 according to a new report by ...
- Prostate Cancer Diagnostics and Minimally Invasive Treatments Markets, 2023on October 17, 2019 at 3:30 am
DUBLIN, Oct. 17, 2019 /PRNewswire/ -- The "Prostate Cancer Diagnostics and Minimally Invasive Treatments Market: US, 5EU Markets, Japan and RoW" report has been added to ResearchAndMarkets.com's ...
- A precision drug for prostate cancer may slow the disease’s spreadon October 16, 2019 at 4:06 am
A drug used to treat breast and ovarian cancers tied to certain genetic mutations may help combat some of the most severe cases of prostate cancer. Overall in men given olaparib, the disease ...
- For low-risk prostate cancer, active surveillance often beats surgeryon October 16, 2019 at 2:03 am
The most common type of cancer in the United States is prostate cancer, and it is the second-most common cause of cancer deaths in U.S. men behind only lung cancer. According to the National Cancer ...
- MNSBC 'Hardball': Chris Matthews had prostate cancer surgeryon October 15, 2019 at 7:32 am
On Monday night, Matthews' fill in, Steve Kornacki, shared that Matthews had undergone surgery for prostate cancer and is currently recovering. "Before we go tonight, Chris hasn’t been here the last ...
- Free prostate cancer screeningson October 14, 2019 at 1:05 pm
BRIDGEPORT — Bridgeport Hospital, 267 Grant St., will host free prostate cancer screenings in the first-floor MedEase Unit from 3:30 to 6:30 p.m. Nov. 12, sponsored by Smilow Cancer Hospital and Yale ...
- Elton John Opens Up About Virus That 'Nearly Killed' Him After Prostate Cancer Surgeryon October 14, 2019 at 10:01 am
55am PDT The music icon made the decision to have his prostate gland removed when he was diagnosed with prostate cancer in 2017, a disease that impacts 1 in 9 men. “I said, ‘I don’t care, take it out, ...
via Bing News